Tag: Parathyroid carcinoma

In 2004, cinacalcet was approved by the FDA as the first agent in its class, definitively answering the question, 'What category is cinacalcet?' and ushering in a new treatment option for hyperparathyroidism. This medication is classified as a calcimimetic agent and is used to manage specific conditions involving overactive parathyroid glands.

A 2024 meta-analysis revealed that the global prevalence of secondary hyperparathyroidism (SHPT) due to chronic kidney disease (CKD) is approximately 49.5% [1.7.1, 1.7.2]. A key medication to manage this is cinacalcet, but what's another name for cinacalcet? The most common brand name is Sensipar [1.2.1].

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease (CKD), with a global prevalence estimated at 49.5%. To manage this and related conditions, a key question for patients and providers is, **what is Cinacalcet?** It's a vital medication for controlling hormone levels.

According to a 2013 meta-analysis, Cinacalcet significantly reduces the need for parathyroidectomy in patients with chronic kidney disease on dialysis. A calcimimetic drug, Cinacalcet tablets are primarily used to manage specific conditions involving overactive parathyroid glands and high calcium levels in the blood. This medication works by increasing the sensitivity of the body's calcium-sensing receptors, which in turn lowers parathyroid hormone (PTH) and calcium levels.